CeriBell, Inc. Common Stock (CBLL) is a publicly traded Healthcare sector company. As of May 21, 2026, CBLL trades at $18.11 with a market cap of $629.09M and a P/E ratio of -12.18. CBLL moved +6.66% today. Year to date, CBLL is -13.02%; over the trailing twelve months it is -0.44%. Its 52-week range spans $10.01 to $32.75. Analyst consensus is strong buy with an average price target of $28.50. Rallies surfaces CBLL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
CeriBell Grows Revenue 36% to $89M, Expands EEG Platform into Pediatrics and Delirium: CFO said CeriBell ended 2025 with $89M revenue, 36% growth and 88% margin, penetrating 3% of a $2B acute-care EEG market across 647 hospitals. Pediatric EEG launch in Q2 and FDA clearance for delirium expanded total addressable market to $3.5B, while breakthrough stroke detection designation paves way for new algorithms.
| Metric | Value |
|---|---|
| Price | $18.11 |
| Market Cap | $629.09M |
| P/E Ratio | -12.18 |
| EPS | $-1.46 |
| Dividend Yield | 0.00% |
| 52-Week High | $32.75 |
| 52-Week Low | $10.01 |
| Volume | 303.61K |
| Avg Volume | 0 |
| Revenue (TTM) | $89.06M |
| Net Income | $-53.41M |
| Gross Margin | 87.89% |
6 analysts cover CBLL: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $28.50.